Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial

Transplant Infectious Disease : an Official Journal of the Transplantation Society
D NeofytosK A Marr

Abstract

Voriconazole (VOR) levels are highly variable, with potential implications to both efficacy and safety. We hypothesized that VOR therapeutic drug monitoring (TDM) will decrease the incidence of treatment failures and adverse events (AEs). We initiated a prospective, randomized, non-blinded multicenter study to compare clinical outcomes in adult patients randomized to standard dosing (clinician-driven) vs. TDM (doses adjusted based on levels). VOR trough levels were obtained on day 5, 14, 28, and 42 (or at completion of drug; ± 3 days). Real-time dose adjustments were made to maintain a range between 1-5 μg/mL on the TDM-arm, while levels were assessed retrospectively in the standard-arm. Patient questionnaires were administered to assess subjective AEs. The study was discontinued prematurely, after 29 patients were enrolled. Seventeen (58.6%) patients experienced 38 AEs: visual changes (22/38, 57.9%), neurological symptoms (13/38, 34.2%), and liver abnormalities (3/38, 7.9%). VOR was discontinued in 7 (25%) patients because of an AE (4 standard-arm, 3 TDM-arm). VOR levels were frequently out of range in the standard-arm (8 tests >5 μg/mL; 9 tests <1 μg/mL). Three dose changes occurred in the TDM-arm for VOR levels <1 μg/mL. Lev...Continue Reading

References

Sep 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R AllyUNKNOWN Esophageal Candidiasis Study Group
Nov 28, 2001·Clinical and Experimental Dermatology·D W Denning, C E Griffiths
Jan 25, 2002·The New England Journal of Medicine·Thomas J WalshUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group
Jan 25, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W DenningHartmut Lode
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Oct 18, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L Ostrosky-ZeichnerJ H Rex
Oct 16, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aileen E BoydDavid W Denning
Dec 4, 2004·Pediatric Dermatology·Melissa RubensteinDenise Metry
Apr 29, 2005·Journal of the American Academy of Dermatology·Andrew J RacetteAnngela Park
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kate L McCarthyMichael Whitby
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andres PascualOscar Marchetti
Jan 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshUNKNOWN Infectious Diseases Society of America
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Jul 22, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brahm H SegalBen E De Pauw
Sep 20, 2008·Clinical Medicine & Research·Anurag N Malani, David M Aronoff
Nov 20, 2008·The Annals of Pharmacotherapy·Ashley HowardAnjly Sheth
Jan 28, 2009·Antimicrobial Agents and Chemotherapy·Brad MoriyamaThomas J Walsh
Jul 4, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Jul 5, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wan Beom ParkKyung-Sang Yu
Nov 2, 2012·Antimicrobial Agents and Chemotherapy·Imke H BartelinkMarc Bierings
Jan 1, 2014·The Journal of Antimicrobial Chemotherapy·H Ruth AshbeeWilliam W Hope
Feb 21, 2014·The Journal of Antimicrobial Chemotherapy·Michael J DoltonAndrew J McLachlan
May 24, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anurag N MalaniCarol A Kauffman
Sep 17, 2014·Antimicrobial Agents and Chemotherapy·Marjolijn J P van WanrooyJan-Willem C Alffenaar
Jan 15, 2015·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Michel LaverdiereYves Théorêt

❮ Previous
Next ❯

Citations

Nov 8, 2016·Virulence·Ya-Lin ChangYing-Lien Chen
Mar 27, 2018·Immunity, Inflammation and Disease·Evan LiDavid B Corry
May 7, 2021·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Sahar YousefianFarzad Kobarfard
Oct 23, 2021·Medical Mycology·Stefan KlugeTobias Lahmer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.